WAYNE, Pa., Aug. 1, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/optr) is investigating potential claims against the board of directors of Optimer Pharmaceuticals, Inc. ("Optimer" or the "Company") (NASDAQ: OPTR) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Cubist Pharmaceuticals, Inc. in a deal valued at approximately $801 million.
Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Optimer for not acting in the Company's shareholders' best interests in connection with the sale process. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at firstname.lastname@example.org or visit: www.rmclasslaw.com/cases/optr.
Under the terms of the proposed transaction, Optimer's stockholders will receive $10.75 in cash for each share of Optimer common stock they own. Optimer shareholders would also receive one Contingent Value Right for each Optimer share they own, which could yield additional cash consideration of up to $5.00 per share.
If you own shares of Optimer would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/optr. You may also email Mr. Maniskas at email@example.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
SOURCE Ryan & Maniskas, LLP